AIDSVAX results: An answer, or just more questions?

被引：7

作者：

Johnston, R ^{[1
]}

机构：

[1] Amer Fdn AIDS Res, New York, NY 10005 USA

来源：

AIDS PATIENT CARE AND STDS | 2003年 / 17卷 / 02期

关键词：

D O I：

10.1089/108729103321150764

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Some time within the next few weeks, VaxGen is expected to announce results of the Phase III trials of its first vaccine candidate based on a bivalent HIV envelope gp120, AIDSVAX B/B. Interpretation of these results will probably not be straightforward and will likely lead to many more unanswered questions. Following is a description of some of the key issues involved.

引用

页码：47 / 51

页数：5

共 15 条

[1] EFFECT OF DOSE AND IMMUNIZATION SCHEDULE ON IMMUNE-RESPONSE OF BABOONS TO RECOMBINANT GLYCOPROTEIN-120 OF HIV-1 [J].

ANDERSON, KP ;

LUCAS, C ;

HANSON, CV ;

LONDE, HF ;

IZU, A ;

GREGORY, T ;

AMMANN, A ;

BERMAN, PW ;

EICHBERG, JW .

JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (06) :960-969

[2] Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes [J].

Barouch, DH ;

Kunstman, J ;

Kuroda, MJ ;

Schmitz, JE ;

Santra, S ;

Peyerl, FW ;

Krivulka, GR ;

Beaudry, K ;

Lifton, MA ;

Gorgone, DA ;

Montefiori, DC ;

Lewis, MG ;

Wolinsky, SM ;

Letvin, NL .

NATURE, 2002, 415 (6869) :335-339

[3] Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand [J].

Berman, PW ;

Huang, W ;

Riddle, L ;

Gray, AM ;

Wrin, T ;

Vennari, J ;

Johnson, A ;

Klaussen, M ;

Prashad, H ;

Köhne, C ;

DeWit, C ;

Gregory, TJ .

VIROLOGY, 1999, 265 (01) :1-9

[4]

Berman PW, 1998, AIDS RES HUM RETROV, V14, pS277

[5] HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 CHALLENGE OF CHIMPANZEES IMMUNIZED WITH RECOMBINANT ENVELOPE GLYCOPROTEIN GP120 [J].

BERMAN, PW ;

GROOPMAN, JE ;

GREGORY, T ;

CLAPHAM, PR ;

WEISS, RA ;

FERRIANI, R ;

RIDDLE, L ;

SHIMASAKI, C ;

LUCAS, C ;

LASKY, LA ;

EICHBERG, JW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) :5200-5204

[6] PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].

BERMAN, PW ;

GREGORY, TJ ;

RIDDLE, L ;

NAKAMURA, GR ;

CHAMPE, MA ;

PORTER, JP ;

WURM, FM ;

HERSHBERG, RD ;

COBB, EK ;

EICHBERG, JW .

NATURE, 1990, 345 (6276) :622-625

[7] PROPHYLACTIC VACCINES, RISK BEHAVIOR-CHANGE, AND THE PROBABILITY OF ERADICATING HIV IN SAN-FRANCISCO [J].

BLOWER, SM ;

MCLEAN, AR .

SCIENCE, 1994, 265 (5177) :1451-1454

[8] A controlled trial of a human papillomavirus type 16 vaccine [J].

Koutsky, LA ;

Ault, KA ;

Wheeler, CM ;

Brown, DR ;

Barr, E ;

Alvarez, FB ;

Chiacchierini, LM ;

Jansen, KU .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651

[9] HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites [J].

Kwong, PD ;

Doyle, ML ;

Casper, DJ ;

Cicala, C ;

Leavitt, SA ;

Majeed, S ;

Steenbeke, TD ;

Venturi, M ;

Chaiken, I ;

Fung, M ;

Katinger, H ;

Parren, PWLH ;

Robinson, J ;

Van Ryk, D ;

Wang, LP ;

Burton, DR ;

Freire, E ;

Wyatt, R ;

Sodroski, J ;

Hendrickson, WA ;

Arthos, J .

NATURE, 2002, 420 (6916) :678-682

[10] AIDSVAX® (MN) in Bangkok injecting drug users:: A report on safety and immunogenicity, including macrophage-tropic virus neutralization [J].

Migasena, S ;

Suntharasamai, P ;

Pitisuttithum, P ;

Kitayaporn, D ;

Wasi, C ;

Huang, W ;

Vanichseni, S ;

Koompong, C ;

Kaewkungwal, J ;

Raktham, S ;

Ippolito, T ;

Hanson, C ;

Gregory, T ;

Heyward, WL ;

Berman, P ;

Francis, D .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (07) :655-663

← 1 2 →